How effective is venetoclax/venetoclax alone in treating leukemia?

Venetoclax/Venetoclax, as an oral B-cell lymphoma factor-2 (BCL-2) inhibitor, has become an important drug in the treatment of specific leukemias, especially chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). At the same time, chemotherapy, as a traditional treatment method, uses chemical drugs to affect the growth and division of cancer cells.

So, can venetoclax alone achieve the desired therapeutic effect without chemotherapy? The answer to this question is not static, but is affected by multiple factors such as the patient's specific condition, physical condition, leukemia type and its stage.

Venetoclax is a targeted drug that has shown significant therapeutic effects in certain types of leukemia. In early stages of the disease or in milder cases, it is possible to achieve good therapeutic results with venetoclax alone. However, in cases where the disease is more severe or the disease progresses rapidly, venetoclax alone may not be able to control the disease, and other treatments such as chemotherapy may be needed in combination. Although chemotherapy can effectively kill cancer cells, it can also cause damage to healthy cells and cause a series of adverse reactions. Therefore, venetoclax alone may be a better treatment option for patients who are in poor health and cannot tolerate the side effects of chemotherapy.

Different types and stages of leukemia also respond differently to treatment. In some types of leukemia, venetoclax may show better efficacy; while for other types or advanced leukemia, a comprehensive treatment strategy including chemotherapy, radiotherapy, immunotherapy, etc. may be needed.